Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-based Conditioning for Allogeneic SCT in Hodgkin's
NCT00385788Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2005
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in Hodgkin lymphoma (HL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Transplant Related Mortality Rate. Started Jul 2005; status: completed.
02
Drugs
gemcitabine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00385788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385788.